Source comparison
HGH Fragment 176-191 vs AOD-9604: Research Application Comparison
Amino Acid Sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly (positions 176–191 of hGH) Identical. Same 15-amino-acid sequence No molecular difference. Naming reflects clinical development history vs biochemical nomenclature Molecular Weight
This comparison does not assign a generated winner or score.
- Amino Acid Sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly (positions 176–191 of hGH)
- Identical. Same 15-amino-acid sequence
- No molecular difference. Naming reflects clinical development history vs biochemical nomenclature
- Molecular Weight
- 1817 Da
- Identical mass. Confirmed via mass spectrometry
- Mechanism of Action
- Activates beta-3 adrenergic receptors on adipocytes; stimulates hormone-sensitive lipase without IGF-1 upregulation
- Identical mechanism. Lipolytic activity without growth receptor binding
- Same receptor pathway. Both bypass hGH receptor binding and mitogenic effects
- Clinical Development Status
- Research-grade peptide; no therapeutic approval
- Advanced to Phase IIb trials (2004–2007); clinical development halted after failure to meet primary endpoint
- AOD-9604 designation tied to failed obesity trials. Fragment 176-191 remains standard research nomenclature
- Typical Research Use
- In vitro adipocyte studies, animal metabolic models, lipolysis mechanism research
- Same applications. Sometimes specified in protocols replicating original Metabolic Pharmaceuticals studies
- Functionally interchangeable for research purposes; specify based on citation requirements
- Regulatory Pathway
- Supplied as research chemical under laboratory use guidelines; not approved for human administration
- Same regulatory status post-trial termination. Available for research but not therapeutic use
- Both require institutional review board (IRB) approval for any human subject research; neither is FDA-approved